Ianalumab shows a dose-related improvement in disease activity in Sjögren’s syndrome
1. There was a dose-related decrease in disease activity from baseline to 24-weeks for patients on ianalumab compared to placebo. ...
Tag: autoimmune disease
Sonelokimab 120 mg or less showed significant clinical benefit over placebo in patients with plaque psoriasis
1. At 12 weeks, the proportion of patients with an IGA score of 0 or 1 was significantly greater in ...
#VisualAbstract: An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
1. In relatives of patients with type 1 diabetes (T1DM) at risk for disease development, randomization to teplizumab delayed time ...
Teplizumab delays type 1 diabetes diagnosis in high risk patients
1. In relatives of patients with type 1 diabetes (T1DM) at risk for disease development, randomization to teplizumab delayed time ...
Quick Take: Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study
Anti-tumor necrosis factor (TNF) therapies are commonly used in the treatment of patients with moderate to severe Crohn’s disease. However, ...
Childhood antibiotic use not linked to celiac or islet cell autoimmunity
1. In a prospective study of children at-risk for development of type-1 diabetes, antibiotic use was not associated with the ...
Salt intake linked with autoimmune disease
Image: PD 1. High salt concentrations were found to activate a pathway involved in TH17 cell development in mice. 2. ...